New combo tackles tough lung cancer
NCT ID NCT04141644
First seen May 23, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This early-phase trial is testing whether adding the immunotherapy drug ipilimumab (Yervoy) to the targeted therapy osimertinib (Tagrisso) is safe and tolerable for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study involves 24 adults whose cancer is stable on osimertinib alone. Researchers will monitor side effects and look for early signs that the combination shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (DISORDER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
osimertinib (Tagrisso) and ipilimumab (Yervoy)
What this could lead to
If it works, this combination could offer a new treatment option for people with EGFR-mutated lung cancer whose disease is stable on osimertinib alone.
What could go wrong
This is a very early (phase 1), small trial with only 24 participants. The main goal is safety, not proof of effectiveness. Combining these drugs may cause significant side effects, and the benefit may be limited or not confirmed in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.